Literature DB >> 8738623

Intraobserver and interobserver reproducibility of WHO and Gleason histologic grading systems in prostatic adenocarcinomas.

S O Ozdamar1, S Sarikaya, L Yildiz, M K Atilla, B Kandemir, S Yildiz.   

Abstract

In this study a total of 96 patients with prostatic carcinoma were evaluated retrospectively. Sections prepared from paraffin blocks were examined and all cases were scored according to the World Health Organization (WHO) and Gleason grading systems. We investigated intraobserver and interobserver reproducibility of two grading systems in prostatic adenocarcinomas. In our study the intraobserver reproducibilities of the WHO and Gleason systems were 75.0% and 78.1%, respectively. The interobserver reproducibilities of the WHO and Gleason grading systems were 60.4% and 70.8%, respectively. While there was no difference between intraobserver and interobserver variations in the Gleason system (p > 0.05), there was significant difference between intraobserver and interobserver variations in the WHO system (p < 0.05).

Entities:  

Mesh:

Year:  1996        PMID: 8738623     DOI: 10.1007/bf02550141

Source DB:  PubMed          Journal:  Int Urol Nephrol        ISSN: 0301-1623            Impact factor:   2.370


  10 in total

1.  Histological grading of prostatic carcinoma in prostatectomy specimens. Comparison of prognostic accuracy of five grading systems.

Authors:  M P Gallee; F J Ten Kate; P G Mulder; J H Blom; R O van der Heul
Journal:  Br J Urol       Date:  1990-04

2.  Cancer statistics, 1994.

Authors:  C C Boring; T S Squires; T Tong; S Montgomery
Journal:  CA Cancer J Clin       Date:  1994 Jan-Feb       Impact factor: 508.702

Review 3.  Histologic grading of prostate cancer: a perspective.

Authors:  D F Gleason
Journal:  Hum Pathol       Date:  1992-03       Impact factor: 3.466

4.  Gleason grading of prostate cancer: a predictor of survival.

Authors:  P C Sogani; A Israel; P H Lieberman; M L Lesser; W F Whitmore
Journal:  Urology       Date:  1985-03       Impact factor: 2.649

5.  A report of the workshops on the current status of the histologic grading of prostate cancer.

Authors:  G P Murphy; W F Whitmore
Journal:  Cancer       Date:  1979-10       Impact factor: 6.860

6.  Histologic grading of prostatic adenocarcinoma: intraobserver reproducibility of the Mostofi, Gleason and Böcking grading systems.

Authors:  M L Cintra; A Billis
Journal:  Int Urol Nephrol       Date:  1991       Impact factor: 2.370

7.  Grading of prostatic cancer: III. Multivariate analysis of prognostic parameters.

Authors:  F H Schroeder; W C Hop; J H Blom; F K Mostofi
Journal:  Prostate       Date:  1985       Impact factor: 4.104

8.  Prostatic carcinoma reproducibility of histologic grading.

Authors:  H Svanholm; H Mygind
Journal:  Acta Pathol Microbiol Immunol Scand A       Date:  1985-03

Review 9.  A pathologist's view of prostatic carcinoma.

Authors:  F K Mostofi; I A Sesterhenn; C J Davis
Journal:  Cancer       Date:  1993-02-01       Impact factor: 6.860

10.  Histologic grading study of prostate adenocarcinoma: the development of a new system and comparison with other methods--a preliminary study.

Authors:  P N Brawn; A G Ayala; A C Von Eschenbach; D H Hussey; D E Johnson
Journal:  Cancer       Date:  1982-02-01       Impact factor: 6.860

  10 in total
  17 in total

1.  Gleason score and pretreatment prostate-specific antigen in survival among patients with stage D2 prostate cancer.

Authors:  William D Figg; Michael E Franks; David Venzon; Paul Duray; Michael C Cox; W Marston Linehan; W Van Bingham; James A Eastham; Eddie Reed; Oliver Sartor
Journal:  World J Urol       Date:  2004-12-08       Impact factor: 4.226

2.  Automated prostate tissue referencing for cancer detection and diagnosis.

Authors:  Jin Tae Kwak; Stephen M Hewitt; André Alexander Kajdacsy-Balla; Saurabh Sinha; Rohit Bhargava
Journal:  BMC Bioinformatics       Date:  2016-06-01       Impact factor: 3.169

3.  Predicting the risk of harboring high-grade disease for patients diagnosed with prostate cancer scored as Gleason ≤ 6 on biopsy cores.

Authors:  Thomas Seisen; Françoise Roudot-Thoraval; Pierre Olivier Bosset; Aurélien Beaugerie; Yves Allory; Dimitri Vordos; Claude-Clément Abbou; Alexandre De La Taille; Laurent Salomon
Journal:  World J Urol       Date:  2014-07-02       Impact factor: 4.226

4.  Multiview boosting digital pathology analysis of prostate cancer.

Authors:  Jin Tae Kwak; Stephen M Hewitt
Journal:  Comput Methods Programs Biomed       Date:  2017-02-22       Impact factor: 5.428

5.  Upgrading and downgrading of prostate needle biopsy specimens: risk factors and clinical implications.

Authors:  Stephen J Freedland; Christopher J Kane; Christopher L Amling; William J Aronson; Martha K Terris; Joseph C Presti
Journal:  Urology       Date:  2007-03       Impact factor: 2.649

Review 6.  Reproducibility and reliability of tumor grading in urological neoplasms.

Authors:  Rainer Engers
Journal:  World J Urol       Date:  2007-09-09       Impact factor: 4.226

7.  Interobserver reproducibility of Gleason grading: evaluation using prostate cancer tissue microarrays.

Authors:  M Burchardt; R Engers; M Müller; T Burchardt; R Willers; J I Epstein; R Ackermann; H E Gabbert; A de la Taille; M A Rubin
Journal:  J Cancer Res Clin Oncol       Date:  2008-04-08       Impact factor: 4.553

8.  The use of Raman spectroscopy to differentiate between different prostatic adenocarcinoma cell lines.

Authors:  P Crow; B Barrass; C Kendall; M Hart-Prieto; M Wright; R Persad; N Stone
Journal:  Br J Cancer       Date:  2005-06-20       Impact factor: 7.640

9.  BRCA2 mutations should be screened early and routinely as markers of poor prognosis: evidence from 8,988 patients with prostate cancer.

Authors:  Ming Cui; Xian-Shu Gao; Xiaobin Gu; Wei Guo; Xiaoying Li; Mingwei Ma; Shangbin Qin; Xin Qi; Mu Xie; Chuan Peng; Yun Bai
Journal:  Oncotarget       Date:  2017-06-20

10.  Prostate cancer in male BRCA1 and BRCA2 mutation carriers has a more aggressive phenotype.

Authors:  A Mitra; C Fisher; C S Foster; C Jameson; Y Barbachanno; J Bartlett; E Bancroft; R Doherty; Z Kote-Jarai; S Peock; D Easton; R Eeles
Journal:  Br J Cancer       Date:  2008-01-08       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.